{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:04:53Z","timestamp":1780085093583,"version":"3.54.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T00:00:00Z","timestamp":1584144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T00:00:00Z","timestamp":1584144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s40261-020-00899-2","type":"journal-article","created":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T08:02:49Z","timestamp":1584172969000},"page":"387-394","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%: A Review in Post-Operative Inflammation and Pain Following Ocular Surgery"],"prefix":"10.1007","volume":"40","author":[{"given":"Connie","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J.","family":"Keam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Shirley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahiya Y.","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,14]]},"reference":[{"issue":"10","key":"899_CR1","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.ophtha.2014.04.035","volume":"121","author":"L Kessel","year":"2014","unstructured":"Kessel L, Tendal B, Jorgensen KJ, et al. Post-cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti-inflammatory eye drops: a systematic review. Ophthalmology. 2014;121(10):1915\u201324.","journal-title":"Ophthalmology"},{"issue":"1","key":"899_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/00055735-200102000-00002","volume":"12","author":"SM El-Harazi","year":"2001","unstructured":"El-Harazi SM, Feldman RM. Control of intra-ocular inflammation associated with cataract surgery. Curr Opin Ophthalmol. 2001;12(1):4\u20138.","journal-title":"Curr Opin Ophthalmol"},{"key":"899_CR3","first-page":"215","volume":"25","author":"CL Salinger","year":"2019","unstructured":"Salinger CL, Gaynes BI, Rajpal RK. Innovations in topical ocular corticosteroid therapy for the management of postoperative ocular inflammation and pain. Am J Manag Care. 2019;25:215\u201326.","journal-title":"Am J Manag Care"},{"issue":"3","key":"899_CR4","doi-asserted-by":"publisher","first-page":"150","DOI":"10.4103\/0974-620X.192268","volume":"9","author":"A Malik","year":"2016","unstructured":"Malik A, Sadafale A, Gupta YK, et al. A comparative study of various topical nonsteroidal anti-inflammatory drugs to steroid drops for control of post cataract surgery inflammation. Oman J Ophthalmol. 2016;9(3):150\u20136.","journal-title":"Oman J Ophthalmol"},{"key":"899_CR5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40123-013-0020-5","volume":"2","author":"U Pleyer","year":"2013","unstructured":"Pleyer U, Ursell PG, Rama P. Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they all the same? Ophthalmol Ther. 2013;2:55\u201372.","journal-title":"Ophthalmol Ther"},{"key":"899_CR6","unstructured":"Bausch & Lomb Incorporated. LOTEMAX SM (loteprednol etabonate ophthalmic gel) 0.38%, for topical ophthalmic use: US prescribing information. 2019. https:\/\/www.fda.gov. Accessed 17 Feb 2020."},{"issue":"1","key":"899_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2165\/00002018-200225010-00004","volume":"25","author":"CNJ McGhee","year":"2002","unstructured":"McGhee CNJ, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids. Drug Saf. 2002;25(1):33\u201355.","journal-title":"Drug Saf"},{"issue":"11","key":"899_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s11095-018-2498-y","volume":"35","author":"J Shen","year":"2018","unstructured":"Shen J, Lu GW, Hughes P. Targeted ocular drug delivery with pharmacokinetic\/pharmacodynamic considerations. Pharm Res. 2018;35(11):217.","journal-title":"Pharm Res"},{"issue":"9","key":"899_CR9","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s40265-013-0073-8","volume":"73","author":"KA Lyseng-Williamson","year":"2013","unstructured":"Lyseng-Williamson KA. Loteprednol etabonate ophthalmic gel 0.5%: a review of its use in post-operative inflammation and pain following ocular surgery. Drugs. 2013;73(9):949\u201358.","journal-title":"Drugs"},{"key":"899_CR10","first-page":"299","volume":"7","author":"MJ Coffey","year":"2013","unstructured":"Coffey MJ, Decory HH, Lane SS. Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop. Clin Ophthalmol. 2013;7:299\u2013312.","journal-title":"Clin Ophthalmol."},{"key":"899_CR11","unstructured":"Bausch & Lomb Incorporated. LOTEMAX (loteprednol etabonate ophthalmic gel) 0.5%, for topical ophthalmic use: US prescribing information. 2018. https:\/\/www.fda.gov. Accessed 17 Feb 2020."},{"key":"899_CR12","unstructured":"Bausch & Lomb Incorporated. LOTEMAX (loteprednol etabonate ophthalmic suspension) 0.5%, for topical ophthalmic use: US prescribing information. 1998. https:\/\/www.fda.gov. Accessed 17 Feb 2020."},{"key":"899_CR13","unstructured":"Bausch & Lomb Incorporated. LOTEMAX (loteprednol etabonate ophthalmic ointment) 0.5%, for topical ophthalmic use: US prescribing information. 2011. https:\/\/www.fda.gov. Accessed 17 Feb 2020."},{"key":"899_CR14","unstructured":"Kala Pharmaceuticals Inc. INVELTYS (loteprednol etabonate ophthalmic suspension) 1%, for topical ophthalmic use: US prescribing information. 2018. https:\/\/www.fda.gov. Accessed 17 Feb 2020."},{"issue":"5","key":"899_CR15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1089\/jop.2018.0136","volume":"35","author":"ME Cavet","year":"2019","unstructured":"Cavet ME, Glogowski S, Lowe ER, et al. Rheological properties, dissolution kinetics, and ocular pharmacokinetics of loteprednol etabonate (submicron) ophthalmic gel 0.38%. J Ocul Pharmacol Ther. 2019;35(5):291\u2013300.","journal-title":"J Ocul Pharmacol Ther."},{"issue":"4","key":"899_CR16","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/14656566.2018.1439920","volume":"19","author":"TL Comstock","year":"2018","unstructured":"Comstock TL, Sheppard JD. Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid. Expert Opin Pharmacother. 2018;19(4):337\u201353.","journal-title":"Expert Opin Pharmacother"},{"key":"899_CR17","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.2147\/OPTH.S210597","volume":"13","author":"R Fong","year":"2019","unstructured":"Fong R, Cavet ME, DeCory H, et al. Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two phase III clinical studies. Clin Ophthalmol. 2019;13:1427\u201338.","journal-title":"Clin Ophthalmol."},{"issue":"10","key":"899_CR18","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.jcrs.2018.06.056","volume":"44","author":"R Fong","year":"2018","unstructured":"Fong R, Silverstein BE, Peace JH, et al. Submicron loteprednol etabonate ophthalmic gel 0.38% for the treatment of inflammation and pain after cataract surgery. J Cataract Refract Surg. 2018;44(10):1220\u20139.","journal-title":"J Cataract Refract Surg."},{"key":"899_CR19","first-page":"9","volume":"59","author":"JL Vittitow","year":"2018","unstructured":"Vittitow JL, LoBue T, Martel J. Safety and efficacy of a novel submicron loteprednol etabonate gel in the treatment of inflammation and pain post-cataract surgery [abstract no. 2235 plus poster]. Invest Ophthalmol Vis Sci. 2018;59:9.","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"899_CR20","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1167\/iovs.16-20903","volume":"58","author":"S Datta","year":"2017","unstructured":"Datta S, Baudouin C, Brignole-Baudouin F, et al. The eye drop preservative benzalkonium chloride potently induces mitochondrial dysfunction and preferentially affects LHON mutant cells. Invest Ophthalmol Vis Sci. 2017;58:2406\u201312.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"899_CR21","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s12325-016-0315-8","volume":"33","author":"JD Sheppard","year":"2016","unstructured":"Sheppard JD, Comstock TL, Cavet ME. Impact of the topical ophthalmic corticosteroid loteprednol etabonate on intraocular pressure. Adv Ther. 2016;33:532\u201352.","journal-title":"Adv Ther."},{"issue":"4","key":"899_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ophtha.2016.09.027","volume":"124","author":"RJ Olson","year":"2017","unstructured":"Olson RJ, Braga-Mele R, Chen SH, et al. Cataract in the adult eye Preferred Practice Pattern\u00ae. Ophthalmology. 2017;124(4):1\u2013119.","journal-title":"Ophthalmology"}],"updated-by":[{"DOI":"10.1007\/s40261-020-00993-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T00:00:00Z","timestamp":1607904000000}}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00899-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-020-00899-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00899-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T22:58:21Z","timestamp":1627685901000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-020-00899-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,14]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["899"],"URL":"https:\/\/doi.org\/10.1007\/s40261-020-00899-2","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,14]]},"assertion":[{"value":"14 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2020","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40261-020-00993-5","URL":"https:\/\/doi.org\/10.1007\/s40261-020-00993-5","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Connie Kang, Susan J. Keam, Matt Shirley and Yahiya Y. Syed are salaried employees of Adis International Ltd\/Springer Nature, are responsible for the article content and declare no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}